Back to top

Image: Bigstock

Moleculin Biotech (MBRX) Jumps: Stock Rises 8.5%

Read MoreHide Full Article

Moleculin Biotech, Inc. MBRX was a big mover last session, as the company saw its shares rise nearly 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company —as the stock is now up 26% in the past one-month time frame.

The company has seen one positive estimate revision in the past few months, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few months, suggesting that more solid trading could be ahead for Moleculin Biotech. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.

Moleculin Biotech currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%. 

Moleculin Biotech, Inc. Price

Another stock worth considering in the Medical - Biomedical and Genetics industry is Arcus Biosciences, Inc. (RCUS - Free Report) which carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by referendums and legislation, this industry is expected to blast from an already robust $17.7 billion in 2019 to a staggering $73.6 billion by 2027. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot stocks we're targeting >>


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Arcus Biosciences, Inc. (RCUS) - free report >>